Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene Delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Gene Therapy

Background:

• Developing safe and efficient nonviral gene delivery systems is crucial for advancing gene therapy.
• Human serum albumin (HSA) nanoparticles offer a biocompatible platform for gene delivery applications.

Purpose of the Study:

• To develop and optimize ligand-modified HSA nanoparticles for enhanced gene delivery.
• To investigate the impact of glutaraldehyde cross-linking degree on nanoparticle performance.
• To evaluate the transfection potential of RGD- and Tat-modified HSA nanoparticles.

Main Methods:

• HSA nanoparticles were synthesized and characterized.
• Nanoparticles were loaded with plasmid DNA and surface-functionalized with arginine-glycine-aspartate (RGD) and HIV-1 transactivator of transduction sequence (Tat) ligands.
• In vitro transfection efficiency of modified nanoparticles was assessed under optimized conditions.

Main Results:

• Varying glutaraldehyde cross-linking degrees influenced nanoparticle properties for gene delivery.
• Tat-modified HSA nanoparticles exhibited superior transfection potential compared to RGD-modified nanoparticles.
• Optimal incubation conditions were identified for maximizing transfection efficiency.

Conclusions:

• Ligand-functionalized HSA nanoparticles are effective tools for efficient gene therapy.
• Tat-modified HSA nanoparticles, particularly those with lower cross-linking, represent a promising strategy for safe and effective gene delivery.